Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Biostem Technologies Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The actions are distributed across 2 distinct examiners and 2 distinct art units, rather than being concentrated with one examiner or unit.
MOORE, JOHN DAVID is the busiest examiner, with 1 pending matter. Counsel can use the separate assignments to track prosecution independently and identify whether different examination approaches affect claim scope or response timing.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOORE, JOHN DAVID | 1 | 61.1% | +28.3% |
| FOX, ALLISON M | 1 | 71.0% | +35.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18858536 | MULTI-PART PROCESSED HUMAN AMNIOTIC COMPOSITION AND METHODS OF MAKING AND USING THEREOF FOR TREATMENT OF PEYRONIE'S DISEASE | MOORE, JOHN DAVID | — |
| 18517338 | TWO-PART CLOTTING COMPOSITION AND METHODS OF MAKING AND USING THEREOF | FOX, ALLISON M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18858536 | MULTI-PART PROCESSED HUMAN AMNIOTIC COMPOSITION AND METHODS OF MAKING AND USING THEREOF FOR TREATMENT OF PEYRONIE'S DISEASE | MOORE, JOHN DAVID | — |
| 18517338 | TWO-PART CLOTTING COMPOSITION AND METHODS OF MAKING AND USING THEREOF | FOX, ALLISON M | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18858536 | MULTI-PART PROCESSED HUMAN AMNIOTIC COMPOSITION AND METHODS OF MAKING AND USING THEREOF FOR TREATMENT OF PEYRONIE'S DISEASE | MOORE, JOHN DAVID | 1638 | §102§103 | Non-Final OA | — | Pending | Oct 21, 2024 |
| 18517338 | TWO-PART CLOTTING COMPOSITION AND METHODS OF MAKING AND USING THEREOF | FOX, ALLISON M | 1633 | §102§112Other | Final Rejection | — | Pending | Nov 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBiostem Technologies Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
John David Moore has the most, with 1 of Biostem Technologies Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
